Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 217

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 217
---
2.

For the six months ended June
30, 2023, our principal capital expenditures related to laboratory equipment.

For the years ended December
31, 2023 and December 31, 2022, our principal capital expenditures largely related to investment in laboratory equipment.

| 108 |

<div align='center'>MANAGEMENT</div>

Directors and Senior Management

The following table sets forth
certain information about our current directors and senior management. The professional address of each of the directors and officers
is care of Biodexa Pharmaceuticals PLC, Caspian Point, 1 Caspian Way, Cardiff, CF10 4DQ, United Kingdom.

| Name (1)                             |     |     Age at 
 12/31/2024 |     | Position/Title                                                |
| Stephen Stamp                        |     |         63 |     | Chief Executive Officer and Chief Financial Officer, Director |
| Stephen Parker (3)(4)                |     |         66 |     | Non-Executive Chairman of the Board of Directors              |
| Simon Turton, Ph.D. (2)(3)(4)        |     |         57 |     | Senior Independent Non-Executive Director                     |
| Sijmen (Simon) de Vries, M.D. (2)(4) |     |         65 |     | Non-Executive Director                                        |
| Ann Merchant (2)(3)                  |     |         59 |     | Non-Executive Director                                        |

__________________________

| (1) | The term of the Board of Directors will expire immediately after the annual general meeting held in 2027 
 for Dr. de Vries, 2026 for Mr. Stamp, Dr. Parker and Ms. Merchant, and 2025 for Dr. Turton.              |

| (2) | Remuneration Committee member |

| (3) | Audit Committee member |

| (4) | Nominations Committee member |

Stephen Stamp has served
as our Chief Executive Officer since March 31, 2020, and our Chief Financial Officer and a member of our Board of Directors since September
2019. Prior to joining the Company, Mr. Stamp served as Chief Executive Officer of Ergomed plc (AIM: ERGO) from December 2017 until January
2019 and Chief Financial Officer from January 2016 to July 2018. From March 2013 until July 2015, Mr. Stamp served as the Chief Financial
Off